Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
G Momekov, D Momekova - Biotechnology & biotechnological …, 2020 - Taylor & Francis
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens.
G Momekov, D Momekova - 2020 - cabidigitallibrary.org
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
[PDF][PDF] Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
G Momekov, D Momekova - … & BIOTECHNOLOGICAL EQUIPMENT, 2020 - academia.edu
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
G Momekov, D Momekova - medRxiv, 2020 - medrxiv.org
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
G Momekov, D Momekova - 2020 - europepmc.org
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
[PDF][PDF] Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view
G Momekov, D Momekova - researchgate.net
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
G Momekov, D Momekova - Biotechnology & Biotechnological …, 2020 - search.proquest.com
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
[PDF][PDF] Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
G Momekov, D Momekova - BIOTECHNOLOGY & …, 2020 - scholar.archive.org
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view
G Momekov, D Momekova - 2020 - pesquisa.bvsalud.org
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view
G Momekov, D Momekova - medRxiv, 2020 - medrxiv.org
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …
SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the …